Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Retrophin Shares Fall 30% on Failed Phase 3 FORT Study

Shares of Retrophin fell to a 52-week low on the news that topline results from its fosmetpantotenate Phase 3 FORT Study for PKNA treatment failed to meet expectations. Biopharmaceutical firm Retrophin Inc. (RTRX:NASDAQ) shares are trading much lower today as the co...
Streetwise Reports | August 26, 2019 |

Empower Clinics increases its digital presence

Empower Clinics Inc. (CSE:EPW) is a Canada-based integrated healthcare company with multi-disciplinary clinics in Canada and the United States. Empower is focused on growing its research and clinical trials segment and pursuing a greater digital presence with healthcare...
Coreena Robertson | August 31, 2023 |

BIGG Digital Assets, Bitcoin Group, Chainalysis - why invest now?

BIGG Digital Assets, Bitcoin Group, Chainalysis - why invest now? The blockchain hype was around two years ago and a lot has changed since then. A consolidation phase has cleared the market and what has remained are the companies and teams that have been able to convin...
Mario Hose | February 13, 2020 |

Revolutionizing immunotherapies with groundbreaking DPX platform

The following is a transcription of the above video, and The Market Online has edited it for clarity . BioVaxys Technology Corp (CSE:BIOV) is a Canadian-based clinical stage biopharmaceutical company focused on improving patient lives with novel immunotherapies. CE...
Lyndsay Malchuk | July 30, 2024 |

ACADIA Pharma's Shares Open 75% Higher on Positive Anti-Psychosis Drug Phase 3 Results

Shares of ACADIA Pharmaceuticals opened up 75% higher today after the company announced that its Phase 3 Study of pimavanserin for the treatment of dementia-related psychosis met its primary endpoint. San Diego, Calif.-based biopharmaceutical company ACADIA Pharmaceu...
Streetwise Reports | September 10, 2019 |

Relmada Therapeutics Stock Soars on Phase 2 Depression Study Results

Shares of Relmada Therapeutics have traded wildly today after it announced Phase 2 results for its anti-depressant drug dextromethadone. The firm's shares have traded 100–200% higher today and the stock was halted several times trading due to extreme price volatility. ...
Streetwise Reports | October 16, 2019 |

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug

Shares of Kiniksa Pharmaceuticals opened nearly 30% higher today after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis. This morning, Hamilton, Bermuda based biopharmaceutical company ...
Streetwise Reports | November 21, 2019 |

NantKwest Shares Jump More than 50% Following JP Morgan Healthcare Conference Presentation

Shares of NantKwest Inc. spiked as much as 85% higher in mid-morning trading setting a new 52-week high price after the company reported a series of positive results at the 38th J.P. Morgan Healthcare Conference in San Francisco. The firm reported that complete responses were ...
Streetwise Reports | January 17, 2020 |

Fate Therapeutics Shares Rise 10% as First Person Treated with Its Anti-Cancer Therapy

Shares of Fate Therapeutics traded higher after the firm reported it has treated the first patient in a first-in-human trial of FT596 for patients with B-cell malignancies and chronic lymphocytic leukemia. Clinical-stage biopharmaceutical company Fate Thera...
Streetwise Reports | April 7, 2020 |

MediciNova Shares Rise 40% on Plans to Initiate COVID-19 ARDS Clinical Trial

Shares of MediciNova traded higher after the company reported that it plans to initiate a clinical study of MN-166 (ibudilast) for COVID-19 acute respiratory distress syndrome. Biopharmaceutical company MediciNova, Inc. yesterday announced that "it will ...
Streetwise Reports | April 13, 2020 |
1 2